Abbott Laboratories (NYSE:ABT) Raised to Outperform at Wolfe Research

Key Points

• Wolfe Research upgraded Abbott Laboratories to “outperform” from “peer perform” and set a $130 price target, implying 17.2% upside. The broader analyst consensus remains “Moderate Buy,” with an average target of $118.67.
• Abbott’s latest quarterly results exceeded expectations, with EPS of $1.31 versus the $1.28 consensus and revenue of $12.59 billion, up 13% year over year. The company guided for fiscal 2026 EPS of $5.45–$5.60.
• Shares opened at $110.92, while institutional investors own approximately 75.18% of the stock; several major funds recently increased their positions.

Abbott Laboratories (NYSE:ABT - Get Free Report) was upgraded by stock analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating in a research note issued on Thursday, Marketbeat Ratings reports. The firm presently has a $130.00 price target on the healthcare product maker's stock. Wolfe Research's target price would indicate a potential upside of 17.20% from the company's current price.

A number of other analysts have also issued reports on ABT. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, April 17th. Oppenheimer cut their price target on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Stifel Nicolaus reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a research note on Friday, April 17th. Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a "neutral" rating for the company in a research report on Friday, April 17th. Finally, Argus cut their target price on shares of Abbott Laboratories from $140.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $118.67.

Abbott Laboratories Stock Up 1.1%

Shares of NYSE ABT opened at $110.92 on Thursday. The stock has a fifty day moving average price of $96.86 and a 200 day moving average price of $99.73. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a market cap of $191.93 billion, a P/E ratio of 35.90, a P/E/G ratio of 2.12 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same quarter in the previous year, the firm posted $1.26 earnings per share. The firm's quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently bought and sold shares of ABT. Brighton Jones LLC increased its position in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after buying an additional 4,755 shares during the period. Sivia Capital Partners LLC grew its position in shares of Abbott Laboratories by 3.5% during the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after acquiring an additional 162 shares during the last quarter. United Bank increased its holdings in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock worth $3,945,000 after acquiring an additional 2,001 shares during the period. Main Street Financial Solutions LLC boosted its stake in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board grew its position in Abbott Laboratories by 25.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after purchasing an additional 292,547 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source